Scientists discover powerful new way to kill prostate cancer cells

Illustration of DALTAC 1 connecting AR and p300
The gears represent the androgen receptor (AR) and p300, which are linked together in a non-native interaction by the wrench, representing DALTAC-1. This leads to inhibition of oncogenic AR transcription and suppression of prostate tumor growth. Credit: Jessica Johnson

Even prostate tumors resistant to standard treatments responded to an experimental molecule in animal studies, raising the possibility of a different approach to advanced disease.

Most cancer drugs work by blocking proteins or signaling pathways that promote tumor growth. Researchers at the University of Michigan Rogel Cancer Center are testing a different approach. Instead of blocking two cancer-causing proteins separately, they developed a molecule that locks them together, disrupting their activity and showing promising results against prostate cancer.

The approach targets the androgen receptor (AR) and a helper protein called p300, which work together to activate genes that fuel prostate cancer growth.

“Our molecule acts as a molecular scaffold, linking these two cancer-causing proteins into an abnormal configuration that traps them in an inactive state,” said the study’s senior author, Arul M. Chinnaiyan, MD, PhD, director of the Michigan Center for Translational Pathology and SP Hicks Professor of Pathology at Michigan Medicine.

“This simultaneously shuts down two oncogenic signaling pathways, enabling highly efficient killing of tumor cells while sparing normal cells. Our preclinical results suggest that this approach may offer a more effective treatment strategy for prostate cancer,” Chinnaiyan said.

Sticking cancer-causing proteins together

The researchers call this approach DALTAC, short for domain alteration chimeras. It builds on a growing field known as chemically induced proximity, which uses small molecules to bring proteins together and change how they work. Related approaches include PROTACs, which trigger the degradation of specific proteins, and chemically induced transcriptional/epigenetic proximity (TCIP), which alters gene regulation.

“Our molecules consist of two inhibitors connected by a carefully designed short linker. By sticking two cancer-causing proteins together, they alter the proteins’ natural interactions,” said study senior author Shaomeng Wang, PhD, Warner-Lambert/Parke-Davis Professor of Medicine, professor of internal medicine, pharmacology and medicinal chemistry, and director of the Michigan Center for Therapeutic Innovation.

Durable responses in treatment-resistant tumors

The team tested DALTAC molecules in prostate cancer cell lines, mouse models, and three-dimensional organoids derived from human cells. The molecules were more effective at killing tumor cells than the combination of separate AR and p300 inhibitors, with less toxicity to normal cells. In animal studies, they produced durable responses and worked against tumors resistant to standard treatments.

“Our optimized molecule is approximately 1,000 times more potent in tumor cells than the combination of inhibitors targeting these proteins separately, while sparing normal cells lacking these interactions. We also optimized the molecules for oral bioavailability, a key step toward developing a pill for patients,” Wang said.

The results, published in Natureis the result of a collaboration between Chinnaiyan’s laboratory, which specializes in prostate cancer biology, and Wang’s laboratory, which specializes in medicinal chemistry and drug discovery.

“These are remarkable preclinical results,” Chinnaiyan said. “The durable responses suggest an opportunity to develop more effective treatment for advanced prostate cancer, including castration-resistant prostate cancer, if these results translate to patients. »

The research is still in the preclinical stage and the approach has not yet been tested in humans.

“Our teams are working closely to identify a drug candidate that can be tested in human clinical trials,” Wang said.

The researchers also believe that changing the way proteins interact could offer a broader strategy for developing treatments for other cancers and protein targets beyond AR and p300.

Reference: “Domain alteration chimeras rewire oncogenic complexes in prostate cancer” by Jie Luo, Jianzhang Yang, Jean Ching-Yi Tien, Mi Wang, Sumit Das, Xiaoju Wang, Eleanor Young, Jelena Tošović, Rahul Mannan, Weiguo Xiang, Xia Jiang, Jocelyn Cai, Yihan Liu, Kenneth Gu, Somnath Mahapatra, Shiting Li, Yitong Yin, Sanjana Eyunni, Abigail J. Todd, Shicheng Jin, Xuhong Cao, Fengyun Su, Stephanie J. Miner, Ranga Sudharshan, Arvind Rao, Abhijit Parolia, Yuanyuan Qiao, Shaomeng Wang and Arul M. Chinnaiyan, November 11, 2026, Nature.
DOI: 10.1038/s41586-026-11262-4

This work was supported by the Rogel Cancer Center Proteomics Resource Facility Shared Resource.

Disclosure: Wang and Chinnaiyan are co-founders and own shares in Medsyn Biopharma. The University of Michigan has filed patents related to DALTAC AR-p300s, which have been licensed to Medsyn. UM received a research contract from Medsyn, for which Wang is the principal investigator.

Never miss a major breakthrough: join the SciTechDaily newsletter.
Follow us on Google and Google News.

Gn Health

Logo